Shire SC Study (A Phase 1/2 randomized, double-blind, placebo-controlled, multicenter, ascending dose, safety and PK/PD study of SHP655 (rADAMTS13) in sickle cell disease at baseline health and during acute vaso-occlusive crisis.)

Administered By

Awarded By

Contributors

Start/End

  • April 9, 2020 - April 15, 2022